We seek to build and invest in the most promising companies across the cell therapy space.
Strategic Focus Area
Cell therapy represents one of the most important therapeutic paradigms emerging to treat some of our most pernicious diseases. It is not only upending how patients are treated, but is also disrupting the way therapies are developed, manufactured, and delivered to patients – which creates new unmet needs and exciting business opportunities.
Delin’s goal is to position itself at the nexus of this opportunity, being the pre-eminent investor in promising cell therapies and the infrastructure that enables their development and commercialization.
adthera is your partner for innovative, optimised-quality, high-technology, cell & gene therapy-focussed development and manufacturing
The uMed platform helps life science clinical and medical teams recruit patients into studies and build evidence in days, not years
First-in-class Bach1 inhibitors with transformative potential as oral therapy for patients with sickle cell disease (SCD) and beyond